Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
N-Terminal Fragment of Brain-Type Natriuretic Peptide (NT-proBNP) as a Prognostic Marker in Patients with Newly Diagnosed Multiple Myeloma Complicated by Dialysis-Dependent Renal Failure.
Semochkin SV, Misyurina EN, Zhelnova EI, Yurova EV, Gagloeva DE, Aref'eva NA, Ushakova AI, Kotenko ON, Tolstykh TN, Sinyavkin DO, Baryakh EA, Yatskov KV, Samsonova IV, Lysenko MA. Semochkin SV, et al. Bull Exp Biol Med. 2019 Jun;167(2):267-271. doi: 10.1007/s10517-019-04506-z. Epub 2019 Jun 24. Bull Exp Biol Med. 2019. PMID: 31236876
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
[Russian experts' clinical guidelines for acute myeloid leukemia treatment in patients less than 60 years of age].
Savchenko VG, Parovichnikova EN, Afanas'ev BV, Gritsaev SV, Semochkin SV, Bondarenko SN, Troitskaia VV, Sokolov AN, Kuz'mina LA, Kliasova GA, Baranova OIu, Lapin VA, Konstantinova TS, Samoĭlova OS, Kaporskaia TS, Shatokhin SV. Savchenko VG, et al. Among authors: semochkin sv. Ter Arkh. 2014;86(7):4-13. Ter Arkh. 2014. PMID: 25314772 Russian.
Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed/refractory AML: a randomized phase 3 trial.
de Botton S, Montesinos P, Schuh AC, Papayannidis C, Vyas P, Wei AH, Ommen H, Semochkin S, Kim HJ, Larson RA, Koprivnikar J, Frankfurt O, Thol F, Chromik J, Byrne J, Pigneux A, Thomas X, Salamero O, Vidriales MB, Doronin V, Döhner H, Fathi AT, Laille E, Yu X, Hasan M, Martin-Regueira P, DiNardo CD. de Botton S, et al. Blood. 2023 Jan 12;141(2):156-167. doi: 10.1182/blood.2021014901. Blood. 2023. PMID: 35714312 Free PMC article. Clinical Trial.
11 results